Lutetium-177 Market Size, Share & Industry Analysis, By Drug (LUTATHERA {lutetium Lu 177 dotatate}, PLUVICTO {lutetium Lu 177 vipivotide tetraxetan}, and Others) By Age Group (Adults and Pediatrics), By Application (Neuroendocrine Tumor, Prostate Cancer, and Others) By End-User (Hospitals, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI112740

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2024
Estimated Year	2025
Forecast Period	2025-2032
Historical Period	2019-2023
Growth Rate	CAGR of 21.8% from 2025-2032
Unit	Value (USD Billion)
Segmentation	By Drug LUTATHERA (lutetium Lu 177 dotatate) PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) Others
	By Age Group Adults Pediatrics
	By Application Neuroendocrine Tumor Prostate Cancer Others
	By End-User Hospitals Specialty Clinics Others
	By Region North America (By Drug, Age Group, Application, End-User, and Country) U.S. Canada Europe ( By Drug, Age Group, Application, End-User, and Country/Sub-region) Germany U.K. France Spain Italy Rest of Europe Asia Pacific ( By Drug, Age Group, Application, End-User, and Country/Sub-region) China Japan India Australia Rest of Asia Pacific Rest of the World ( By Drug, Age Group, Application, and End-User)